Correlation between risk factors for vascular disease and the American urological association symptom score

BJU International

Volumn 99, Issue 1, 2007, Pages 97-100

  Gibbons, Erin P ^a   Colen, John ^a   Nelson, Joel B ^a   Benoit, Ronald M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

AUA symptom score; LUTS; Vascular disease

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; HERBACEOUS AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; REVIEW; SCORING SYSTEM; SMOKING HABIT; SYMPTOMATOLOGY; URINARY TRACT INFECTION;

ADULT; AGED; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATISM; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; VASCULAR DISEASES;

EID: 33845494758     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06548.x     Document Type: Review

References (24)

1. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology 2001; 58 (Suppl. 6a): 5-16
2. Barry MJ, Cockett ATK, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993; 150: 351-8
3. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004; 172: 1390-3
4. Platz EA, Kawachi I, Rimm EB et al. Physical activity and benign prostatic hyperplasia. Arch Intern Med 1998; 158: 2349-56
5. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54: 935-44
6. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol 1997; 146: 609-17
7. Hopps CV, Mulhall JP. Assessment of the impact of Sildenafil citrate on lower urinary tract symptoms (LUTS) in men with erectile dysfunction (ED). J Urol 2003; 1689: 4101a
8. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90: 836-9
9. Hamilton W, Sharp D. Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract 2004; 54: 617-21
10. Roos NP, Wennberg JE, Malenka DJ et al. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med 1989; 320: 1120-4
11. Malenka DJ, Roos N, Fisher ES et al. Further study of the increased mortality following transurethral prostatectomy: a chart-based analysis. J Urol 1990; 144: 224-8
12. Hahn RG, Farahmand BY, Hallin A, Hammar N, Persson PG. Incidence of acute myocardial infarction and cause-specific mortality after transurethral treatments of prostatic hypertrophy. Urology 2000; 55: 236-40
13. Bourke JB, Griffin JP. Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br J Urol 1966; 38: 18-23
14. Sugaya K, Kadekawa K, Ikehara A et al. Influences of lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol 2003; 10: 569-75
15. Namasivayam S, Minhas S, Brooke J, Joyce AD, Prescott S, Eardley I. The evaluation of sexual function in men presenting with symptomatic benign prostatic hyperplasia. Br J Urol 1998; 82: 842-6
16. Ponholzer A, Temml C, Obermayr R, Madersbacher S. Association between lower urinary tract symptoms and erectile dysfunction. Urology 2004; 64: 772-6
17. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005; 47: 824-37
18. Shiri R, Hakkinen JT, Hakama M et al. Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. J Urol 2005; 174: 205-9
19. Burnett AL. Nitric oxide control of lower genitourinary tract functions: a review. Urology 1995; 45: 1071-8
20. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology 1995; 45: 440-6
21. Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997; 33: 1-8
22. Klotz T, Mathers MJ, Bloch W, Nayal W, Engelmann U. Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 1999; 31: 335-41
23. Zakaria L, Anastasiadis AG, Shabsigh R. Common conditions of the aging male: erectile dysfunction, benign prostatic hyperplasia, cardiovascular disease and depression. Int Urol Nephrol 2001; 33: 283-92
24. Berger AP, Deibl M, Leonhartsberger N et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 2005; 96: 1073-8